Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

NCT00088855 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

NIH

Sponsor class

Conditions

DS Stage I Plasma Cell Myeloma
DS Stage II Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma

Interventions

DRUG: Bortezomib
OTHER: Laboratory Biomarker Analysis
DRUG: Pegylated Liposomal Doxorubicin Hydrochloride

Sponsor

National Cancer Institute (NCI)